Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy

NCT03935347 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no accrual

Conditions

Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Unresectable Renal Pelvis Urothelial Carcinoma
Unresectable Ureter Urothelial Carcinoma

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Fludarabine Phosphate
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Autologous Tumor Infiltrating Lymphocytes LN-145
BIOLOGICAL: Aldesleukin

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]